trial

Staccato Loxapine Single Dose PK

NCTId NCT00444028
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 50 (actual)
Sponsored by Alexza Pharmaceuticals, Inc.
Primary completion 2005-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
50 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2005-09
Primary completion
2005-11
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
inhaled Loxapine 0.625 mginhaled Loxapine 1.25 mginhaled Loxapine 2.5 mgInhaled Loxapine 5 mgInhaled Loxapine 10 mg

Sponsors

Alexza Pharmaceuticals, Inc.Lead Sponsor

Investigators

1
Randall Stoltz, MDPrincipal Investigator

Sites

1 total
Evansville, United States

Facts & assertions

4 sourced
Enrollment
50
Phase
PHASE1
Primary Completion Date
2005-11
Status
COMPLETED
relationships
The graph out of here
drug
inhaled Loxapine 0.625 mg
drug
inhaled Loxapine 1.25 mg
drug
inhaled Loxapine 2.5 mg
drug
Inhaled Loxapine 5 mg
drug
Inhaled Loxapine 10 mg
drug
lead_sponsor
Alexza Pharmaceuticals, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Randall Stoltz, MD
person